Bryostatin Treatment of Moderately Severe Alzheimer's Disease
Status:
Recruiting
Trial end date:
2022-11-02
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability, and long-term efficacy of bryostatin 1 (hereafter
referred to as bryostatin) for the treatment of moderately severe Alzheimer's disease (AD).
Phase:
Phase 2
Details
Lead Sponsor:
Neurotrope Bioscience, Inc.
Collaborators:
National Institute on Aging (NIA) National Institutes of Health (NIH)